FDA Brief

Warning letters Drugs

FDA warning letter to

McDaniel Water, LLC

High riskIssued Sep 7, 2021Posted Sep 14, 2021Center for Drug Evaluation and Research | CDER

FDA told McDaniel Water its Black Indian Salve is an unapproved new drug because it is a corrosive topical product sold with disease-treatment claims.

What happened

In July 2021 FDA reviewed McDaniel Water’s product labeling and website, where it took orders for “Black Indian Salve” (also called “Indian Herb,” “X,” and “Black Salve”). FDA found the product was marketed as a dietary supplement despite directions for topical use and ingestion, and that labeling and website claims made it a drug. FDA also said it is labeled to contain bloodroot and zinc chloride, known corrosive agents, and noted a prior warning letter, recall, and safety alert for a similar “Indian Herb” product.

What FDA found

  1. McDaniel Water sold Black Indian Salve as a dietary supplement even though its directions allowed topical use, and topical products are not dietary supplements.

    Section 201(ff)(2)(A)(i) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 321(ff)(2)(A)(i)
  2. Labeling and website claims that Black Indian Salve treats abnormal growths, skin conditions, infections, or cancer make it a drug.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  3. Black Indian Salve is a new drug because it is not generally recognized as safe and effective for its labeled uses.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  4. The company introduced the product into interstate commerce without an FDA-approved drug application.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  5. The product is labeled to contain bloodroot and zinc chloride, known corrosive agents that can damage healthy and diseased tissue and form dead tissue.

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If corrections cannot be completed in that time, the company must explain the delay and when it will finish.

Who should pay attention

  • consumers who buy black salve or Indian Herb products online
  • retailers and online marketplaces that list similar topical salves
  • companies making or selling herbal products with drug-like claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk